Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14296191 | 1.00 | MMP8 (0.32) | MMP8PRKCATSHRCHRM2CHRM4 | |
| SCHEMBL14296154 | 1.00 | MMP8 (0.32) | MMP8PRKCATSHRCHRM2CHRM4 | |
| SCHEMBL17358371 | 0.87 | GRIN2D (0.37) | MMP8TSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL14884195 | 0.87 | GRIN2D (0.37) | MMP8TSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL14884194 | 0.87 | GRIN2D (0.37) | MMP8TSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL14991579 | 0.81 | TSHR (0.32) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL13227842 | 0.81 | MMP8 (0.33) | MMP8FAAH | |
| SCHEMBL13227576 | 0.81 | MMP8 (0.33) | MMP8FAAH | |
| SCHEMBL2172944 | 0.81 | CYP3A4 (0.35) | — | |
| SCHEMBL19472063 | 0.79 | SLC7A5 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | MMP8 2286/4885PRKCA 2406/4885TSHR 3548/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | MMP8 2286/4885PRKCA 2406/4885TSHR 3548/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | MMP8 2286/4885PRKCA 2406/4885TSHR 3548/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | MMP8 3973/4885PRKCA 1551/4885TSHR 4329/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | MMP8 3973/4885PRKCA 1551/4885TSHR 4329/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | MMP8 4140/4885PRKCA 3934/4885TSHR 195/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | MMP8 2160/4885PRKCA 4094/4885TSHR 2332/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | MMP8 2286/4885PRKCA 2406/4885TSHR 3548/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | MMP8 3386/4885PRKCA 2807/4885TSHR 3669/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | MMP8 1916/4885PRKCA 3821/4885TSHR 1621/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | MMP8 2510/4885PRKCA 2318/4885TSHR 3572/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | MMP8 3535/4885PRKCA 3642/4885TSHR 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.